CINECA IRIS Institutional Research Information System

DI DESIDERO, TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.055
AS - Asia 2.080
EU - Europa 1.715
SA - Sud America 268
AF - Africa 112
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 10.242
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.945
SG - Singapore 665
CN - Cina 584
IT - Italia 438
HK - Hong Kong 343
SE - Svezia 291
DE - Germania 229
BR - Brasile 222
VN - Vietnam 182
BG - Bulgaria 153
GB - Regno Unito 139
FR - Francia 131
CA - Canada 88
FI - Finlandia 80
TR - Turchia 80
RU - Federazione Russa 61
IN - India 59
UA - Ucraina 50
CI - Costa d'Avorio 45
JP - Giappone 43
AT - Austria 37
BD - Bangladesh 26
BE - Belgio 20
CH - Svizzera 15
AR - Argentina 14
SN - Senegal 14
PK - Pakistan 13
ZA - Sudafrica 13
IQ - Iraq 12
NG - Nigeria 12
NL - Olanda 12
ES - Italia 11
ID - Indonesia 11
PL - Polonia 11
EC - Ecuador 9
SA - Arabia Saudita 9
MA - Marocco 8
MX - Messico 8
UZ - Uzbekistan 8
LT - Lituania 7
AU - Australia 6
CZ - Repubblica Ceca 6
KR - Corea 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
EG - Egitto 5
PY - Paraguay 5
OM - Oman 4
TN - Tunisia 4
AL - Albania 3
CR - Costa Rica 3
DK - Danimarca 3
HU - Ungheria 3
IE - Irlanda 3
KE - Kenya 3
MY - Malesia 3
NP - Nepal 3
PS - Palestinian Territory 3
RO - Romania 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
BH - Bahrain 2
CL - Cile 2
DZ - Algeria 2
GR - Grecia 2
IL - Israele 2
JM - Giamaica 2
LB - Libano 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PE - Perù 2
PT - Portogallo 2
TH - Thailandia 2
A1 - Anonimo 1
AG - Antigua e Barbuda 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BJ - Benin 1
BW - Botswana 1
CU - Cuba 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GE - Georgia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
GU - Guam 1
IR - Iran 1
JO - Giordania 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NO - Norvegia 1
Totale 10.236
Salva come PNG Salva come JPEG
Città #
Woodbridge 638
Ashburn 580
Fairfield 528
Ann Arbor 507
Chandler 339
Hong Kong 336
Singapore 335
Dallas 330
Houston 329
Santa Clara 313
San Jose 287
Seattle 260
Cambridge 214
Wilmington 205
Serra 193
Sofia 153
Beijing 145
Shanghai 135
New York 112
Boardman 76
Los Angeles 76
Ottawa 72
Princeton 65
Lawrence 59
Des Moines 58
Lauterbourg 55
Dearborn 52
Medford 52
Munich 49
Abidjan 45
Ho Chi Minh City 42
Istanbul 40
Dong Ket 38
Tokyo 38
Council Bluffs 36
London 35
Jacksonville 34
Vienna 32
Hanoi 31
Nanjing 31
Buffalo 28
Milan 28
Frankfurt am Main 27
Izmir 27
Marseille 22
Ogden 21
Redondo Beach 21
San Diego 21
Helsinki 20
Pisa 20
São Paulo 20
The Dalles 20
Brussels 19
Florence 19
Turku 19
Boulder 18
Columbus 17
Düsseldorf 17
Nanchang 16
Falls Church 15
Bremen 14
Dakar 14
Redwood City 14
Fuzhou 12
Lagos 11
Rome 11
Seacroft 11
Bern 10
Lancaster 10
Phoenix 10
Shenyang 10
Guangzhou 9
Hebei 9
Quanzhou 9
Stockholm 9
Mumbai 8
Pune 8
Warsaw 8
Atlanta 7
Denver 7
Dhaka 7
Dülmen 7
Jiaxing 7
Kunming 7
Nuremberg 7
Rho 7
Tashkent 7
Auburn Hills 6
Belo Horizonte 6
Boston 6
Changsha 6
Johannesburg 6
Montreal 6
Norwalk 6
Orem 6
Rio de Janeiro 6
Bexley 5
Da Nang 5
Jüchen 5
Lucca 5
Totale 7.694
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 298
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy 284
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 267
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 255
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 252
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study 240
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 239
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 235
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 226
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 213
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 209
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo 209
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. 206
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. 201
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 194
Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy 194
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 192
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 186
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 182
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 182
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 179
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 177
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 172
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 171
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 168
Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter 168
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 163
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 162
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 156
Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma 155
Agenti melanocortinici per l’impiego nel trattamento terapeutico del melanoma, dei tumori del tratto gastroenterico e del carcinoma tiroideo 148
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 147
Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients? 146
Prevention of capecitabine toxicity using a 5-FU test dose 146
Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1 144
Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors 143
IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 142
Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer 136
MELANOCORTIN AGENTS FOR USE IN THE THERAPEUTIC TREATMENT OF MELANOMA, TUMORS OF THE GASTROINTESTINAL TRACT, AND THYROID CARCINOMA 134
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer 130
Novel Pyrazolopyrimidine Derivatives as Therapeutic Agents for the Treatment of Medullary Thyroid Carcinoma 129
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. 128
null 127
Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. 126
Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation 124
Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells 124
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 121
High frequency ultrasound and photoacoustic imaging for tissue characterization in vivo 121
Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients 120
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer 119
null 114
Phase II clinical trial with pharmacokinetics (PK) and pharmacodynamics (PD) evaluation of metronomic oral vinorelbine (V) and dexamethasone (D) in patients with advanced castration resistant prostate cancer (CRPC): final clinical results 112
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial. 111
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients 109
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. 109
null 108
null 101
null 90
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward 90
null 89
null 79
null 76
Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth 75
Metronomic chemotherapy for triple negative breast cancer? 73
Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-fluorouracil Antitumor Activity In Vitro and In Vivo 71
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer 71
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer 65
Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib 54
null 48
Totale 10.435
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.589
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.589
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021126 0 0 0 0 0 0 0 0 0 0 32 94
2021/2022676 12 45 12 34 130 102 13 28 37 29 36 198
2022/20231.014 118 141 84 93 111 125 6 79 186 6 57 8
2023/2024481 45 44 58 9 62 113 18 22 12 9 35 54
2024/20251.958 8 83 18 128 223 216 161 70 196 249 195 411
2025/20262.118 164 237 346 172 228 161 354 106 138 195 17 0
Totale 10.435